

Molecular basis of ligand-dependent Nurr1-RXR α activation

Xiaoyu Yu^{1,2†}, Jinsai Shang^{2‡}, Douglas J Kojetin^{2,3*§, #†}

¹Skaggs Graduate School of Chemical and Biological Sciences at Scripps Research, Jupiter, United States; ²Department of Integrative Structural and Computational Biology, Scripps Research and UF Scripps Biomedical Research, Jupiter, United States; ³Department of Molecular Medicine, Scripps Research and UF Scripps Biomedical Research, Jupiter, United States

***For correspondence:**
douglas.kojetin@vanderbilt.edu

Present address: [†]Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, United States; [‡]School of Basic Medical Sciences, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, China; [§]Center for Structural Biology, Vanderbilt University School of Medicine, Nashville, United States; [#]Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, United States

Competing interest: The authors declare that no competing interests exist.

Funding: See page 17

Preprinted: 08 November 2022

Received: 18 November 2022

Accepted: 26 April 2023

Published: 27 April 2023

Reviewing Editor: Volker Dötsch, Goethe University, Germany

© Copyright Yu et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract Small molecule compounds that activate transcription of Nurr1-retinoid X receptor alpha (RXR α) (NR4A2-NR2B1) nuclear receptor heterodimers are implicated in the treatment of neurodegenerative disorders, but function through poorly understood mechanisms. Here, we show that RXR α ligands activate Nurr1-RXR α through a mechanism that involves ligand-binding domain (LBD) heterodimer protein-protein interaction (PPI) inhibition, a paradigm distinct from classical pharmacological mechanisms of ligand-dependent nuclear receptor modulation. NMR spectroscopy, PPI, and cellular transcription assays show that Nurr1-RXR α transcriptional activation by RXR α ligands is not correlated with classical RXR α agonism but instead correlated with weakening Nurr1-RXR α LBD heterodimer affinity and heterodimer dissociation. Our data inform a model by which pharmacologically distinct RXR α ligands (RXR α homodimer agonists and Nurr1-RXR α heterodimer selective agonists that function as RXR α homodimer antagonists) operate as allosteric PPI inhibitors that release a transcriptionally active Nurr1 monomer from a repressive Nurr1-RXR α heterodimeric complex. These findings provide a molecular blueprint for ligand activation of Nurr1 transcription via small molecule targeting of Nurr1-RXR α .

Editor's evaluation

This is a fundamental study of the activation process of Nurr1, an orphan nuclear receptor that may be a significant target for the treatment of neurodegenerative disorders. Nurr1 functions as a monomer, but may also heterodimerize with RXR α which represses Nurr1 transcriptional activation. The authors provide compelling evidence for Nurr1 activation through ligand-induced dissociation of an inactive Nurr1-RXR α heterodimer. These data will be important for biochemists and cell biologists working on regulatory / activation mechanisms of nuclear hormone receptors.

Introduction

Nurr1 (nuclear receptor related 1 protein; NR4A2) is a nuclear receptor (NR) transcription factor that is essential for the development, regulation, and maintenance of several important aspects of mammalian brain development and homeostasis. Nurr1 is critical in the development of dopaminergic neurons that are critical for control of movement that degenerates in Parkinson's disease (PD) (*Decressac et al., 2013; Jiang et al., 2005; Zetterström et al., 1997*). Recent studies show that Nurr1 is an important factor in the regulation of neuroinflammation and accumulation of amyloid beta that occurs in the pathogenesis of Alzheimer's disease (AD) (*Jeon et al., 2020; Moon et al., 2019*). These and other studies implicate small molecule activation of Nurr1 as a potential therapeutic strategy in

aging-associated neurodegenerative and dementia disorders characterized by a loss of neuron function (Moutinho et al., 2019).

Although NRs are considered to be ligand-dependent transcription factors, targeting Nurr1 activity with small molecule compounds has remained challenging. Nurr1 contains the conserved NR domain architecture (Weikum et al., 2018) including an N-terminal activation function-1 (AF-1) domain, a central DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD). The classical model of ligand-induced NR transcriptional activation occurs via ligand binding to an orthosteric pocket located in the internal core of the LBD, which stabilizes the activation function-2 (AF-2 surface) in an active conformation resulting in high affinity coactivation interaction to the NR and recruitment of coactivator complexes resulting in chromatin remodeling and increased gene expression. However, crystal structures have revealed properties of Nurr1 LBD that suggest it may function in an atypical ligand-independent manner. The structures show no classical orthosteric ligand-binding pocket volume as well as a reversed 'charge clamp' AF-2 surface that prevents the LBD from interacting with typical NR transcriptional coregulator proteins (Wang et al., 2003). However, solution-state structural studies indicate the Nurr1 LBD is dynamic and can likely expand to bind endogenous ligands (de Vera et al., 2019). Although endogenous and synthetic ligands have been reported to bind and/or regulate Nurr1 activity (Bruning et al., 2019; de Vera et al., 2016; Kim et al., 2015; Rajan et al., 2020; Willems and Merk, 2022), some reported Nurr1 ligands function independent of binding to its LBD (Munoz-Tello et al., 2020). These and other observations have directed efforts to discover small molecule modulators of Nurr1 activity through other mechanisms.

An alternative way to modulate Nurr1 transcription activity is through ligands that target its NR heterodimer-binding partner, retinoid X receptor alpha (RXR α ; NR2B1). Heterodimerization with RXR α represses Nurr1 transcription on monomeric DNA response elements called NBREs (Aarnisalo et al., 2002; Forman et al., 1995) that are present in the promoter regions of genes that regulate dopaminergic signaling including tyrosine hydroxylase (Iwawaki et al., 2000; Kim et al., 2003). The observation that classical pharmacological RXR α agonists enhance Nurr1-RXR α transcription on NBREs (Aarnisalo et al., 2002; Forman et al., 1995; Perlmann and Jansson, 1995; Wallen-Mackenzie et al., 2003) inspired the discovery of RXR α -binding ligands that display biased activation of Nurr1-RXR α heterodimers over other NR-RXR α heterodimers or RXR α homodimers (Giner et al., 2015; Morita et al., 2005; Scheepstra et al., 2017; Spathis et al., 2017; Sundén et al., 2016). However, it remains poorly understood how classical RXR α ligands (pharmacological agonists and antagonists) and Nurr1-RXR α selective agonists impact the structure and function of Nurr1-RXR α .

Here, we tested a set of RXR α ligands in structure-function assays to determine their mechanism of action in regulating Nurr1-RXR α transcriptional activity. Unexpectedly, our studies show that ligand activation of Nurr1-RXR α transcription is not associated with classical pharmacological RXR α agonism, which is defined by a ligand-induced increase in coactivator binding to the RXR α LBD resulting in transcriptional activation. Instead, our data support a model whereby Nurr1-RXR α activating ligands weaken Nurr1-RXR α LBD heterodimer affinity via an allosteric protein-protein interaction (PPI) inhibition mechanism and release a transcriptionally active Nurr1 monomer from the repressive Nurr1-RXR α heterodimer.

Results

RXR α LBD is sufficient for repression of Nurr1 transcription

To confirm the published observation that RXR α represses Nurr1 transcription (Aarnisalo et al., 2002; Forman et al., 1995), we performed a transcriptional reporter assay where SK-N-BE(2) neuronal cells were transfected with a full-length Nurr1 expression plasmid, with or without full-length or domain-truncation RXR α expression plasmids, along with a 3xNBRE-luciferase plasmid containing three copies of the monomeric NBRE DNA-binding response element sequence upstream of luciferase gene (Figure 1a). Cotransfected RXR α expression plasmid repressed Nurr1 transcription, and RXR α truncation constructs show that the RXR α LBD is both necessary and sufficient for repression of Nurr1 transcription (Figure 1b). A slight decrease in Nurr1 transcription is observed with the Δ LBD construct though the effect is not statistically significant. These findings implicate an LBD-driven PPI mechanism with a negligible or minor role for the RXR α DBD, which is consistent with published studies that showed full-length RXR α does not bind to monomeric NBRE sequences via the RXR α DBD, but




Figure 1. Contribution of retinoid X receptor alpha (RXRα) domains on repressing Nurr1 transcription. **(a)** General scheme of the cellular transcriptional reporter assay. **(b)** 3xNBRE-luciferase assay performed in SK-N-BE(2)-C cells; see **Figure 1—source data 1** for data plotted. Data are normalized to empty vector control (n=9 replicates), shown as a box and whiskers plot with boundaries of the box representing the 25th percentile and the 75th percentile, and representative of two or more independent experiments. Statistical testing was performed and p-values were calculated using the Brown-Forsythe and Welch multiple comparisons test of the FL Nurr1 + RXRα constructs conditions relative to FL Nurr1 control condition.

The online version of this article includes the following source data for figure 1:

Source data 1. Nurr1+ retinoid X receptor alpha (RXRα) truncated construct luciferase reporter data.

does interact with Nurr1 that is bound to NBRE DNA sequences via a PPI (Sacchetti et al., 2002). Furthermore, RXR ligands can activate transcription of a Gal4 DBD-Nurr1 LBD fusion protein, but not a Gal4 DBD-Nurr1 LBD mutant (Nurr1^{dim}) that cannot heterodimerize with RXRα (Aarnisalo et al., 2002; Wallen-Mackenzie et al., 2003), which further implicates the RXRα LBD in repression of Nurr1 LBD-mediated transcription.

RXRα ligands display graded Nurr1-RXRα transcriptional activation

We assembled a set of 14 commercially available RXRα-binding ligands (Figure 2) described in the literature as pharmacological RXRα agonists and antagonists; a mixed activity PPARγ-RXR selective modulator (LG100754) that antagonizes RXR homodimers but agonizes PPAR-RXR and RAR-RXR heterodimers (Lala et al., 1996) and two RXRα-binding compounds (BRF110 and HX600) described as selective agonists of Nurr1-RXRα heterodimers (Morita et al., 2005; Spathis et al., 2017). To determine how the ligands influence Nurr1-RXRα transcription, we performed a transcriptional reporter assay where SK-N-BE(2) neuronal cells were transfected with full-length Nurr1 and RXRα expression plasmids and the 3xNBRE-luc plasmid then treated with compound or DMSO control (Figure 3a). Compounds reported as RXRα agonists increase Nurr1-RXRα transcription (Figure 3b), and among




RXR α agonists**RXR α antagonists****Nurr1-RXR α selective agonists**

Figure 2. Retinoid X receptor alpha (RXR α) ligands used in this study. Grouped by pharmacological phenotype, the set includes ligands that classically activate (agonists) or block (antagonists) activation of RXR α homodimers; a mixed activity modulator (LG100754) that antagonizes RXR α homodimers and activates PPAR γ -RXR α and RAR-RXR α heterodimers; and two selective activators of Nurr1-RXR α heterodimers (BRF110 and HX600).

the most efficacious agonist ligands includes endogenous metabolite 9-*cis*-retinoic acid (9cRA) and bexarotene, the latter of which was reported to display biased activation of Nurr1-RXR heterodimers over RXR homodimers (McFarland *et al.*, 2013). RXR α antagonists showed relatively no change or slightly decreased transcription of Nurr1-RXR α . The two Nurr1-RXR α selective agonists, BRF110 and HX600, displayed the highest activity of all compounds tested. Taken together, the transcriptional




Figure 3. Effect of retinoid X receptor alpha (RXR α)-binding ligands on Nurr1-RXR α transcription. **(a)** General scheme of the Nurr1-RXR α /3xNBRE-luciferase cellular transcriptional reporter assay. **(b)** Nurr1-RXR α /3xNBRE-luciferase transcriptional reporter assay performed in SK-N-BE(2)-C cells treated with RXR α ligand (1 μ M) or DMSO (dotted line); see **Figure 3—source data 1** for data plotted. Data are normalized to DMSO (n=9 replicates), represent the mean $\pm$ s.d., and representative of two or more independent experiments. Statistical testing was performed and p-values were calculated using the Brown-Forsythe and Welch multiple comparisons test relative to DMSO control treated condition.

The online version of this article includes the following source data for figure 3:

Source data 1. Retinoid X receptor alpha (RXR α) ligand treated Nurr1-RXR α /3xNBRE3-luciferase reporter data.

reporter data obtained indicates this RXR α ligand set influences Nurr1-RXR α transcription via a graded activation mechanism.

Nurr1-RXR α activation is not correlated with pharmacological RXR α agonism

Agonist binding to the NR LBD stabilizes an active conformation that facilitates coactivator protein interaction at the AF-2 surface via a ‘charge clamp’ mechanism (Savkur and Burris, 2004) that is important for binding LXXLL-containing motifs present within coactivator proteins resulting in an increase in transcription (Kojetin and Burris, 2013). The Nurr1 LBD does not interact with canonical coregulator proteins because it contains a reversed ‘charge clamp’ in its AF-2 surface (Wang et al., 2003), implicating ligand-dependent coactivator interaction with RXR α in the mechanism of Nurr1-RXR α activation.

To determine if there is a correlation between Nurr1-RXR α transcriptional agonism and increased coactivator recruitment to RXR α that results in transcriptional activation within the RXR α ligand set, we performed a time-resolved fluorescence resonance energy transfer (TR-FRET) biochemical assay (Figure 4a) to assess how the compounds affect interaction between the RXR α LBD and a coregulator peptide derived from a cognate coactivator protein PGC-1 α (Delerive et al., 2002; Figure 4b). We also performed a transcriptional reporter assay to determine if there is a correlation between RXR α homodimer-mediated transcription (Figure 4c) and Nurr1-RXR α transcription for the RXR α ligand set. We cotransfected HEK293T cells with a full-length RXR α expression plasmid along with a plasmid containing three copies of the dimeric RXR DNA-binding response element sequence upstream of luciferase gene (3xDR1-luc) then treated the cells with RXR α ligand or DMSO control (Figure 4d). In this analysis, we did not include two RXR α ligands, danthron and rhein, which are colored and cause interference in TR-FRET experiments.

We previously showed that ligands displaying graded pharmacological PPAR γ agonism show a strong correlation between coactivator peptide recruitment to the LBD in a TR-FRET biochemical assay and cellular transcription of full-length PPAR γ (Shang et al., 2019). However, no significant




Figure 4. Compound profiling for pharmacological retinoid X receptor alpha (RXRα) agonism and correlation to Nurr1-RXRα agonism. **(a)** General scheme of the RXRα ligand-binding domain (LBD) time-resolved fluorescence resonance energy transfer (TR-FRET) coactivator peptide interaction assay. **(b)** TR-FRET ratio measured in the presence of DMSO (dotted line) or compound (2–4 μM); see **Figure 4—source data 1** for data plotted. Data are normalized to DMSO control (n=3 biological replicates), represent the mean ± s.d., representative of two or more independent experiments. Statistical testing was performed and p-values were calculated using ordinary one-way ANOVA tests for multiple comparisons with Dunnett corrections relative to DMSO control treated condition. **(c)** General scheme of the RXRα/3xDR1-luciferase cellular transcriptional reporter assay. **(d)** RXRα/3xDR1-luciferase transcriptional reporter assay performed in HEK293T cells treated with compound (1 μM) or DMSO control (dotted line); see **Figure 4—source data 2** for data plotted. Data normalized to DMSO (n=6 replicates), represent the mean ± s.d., and representative of two or more independent experiments. Statistical testing was performed and p-values were calculated using the Brown-Forsythe and Welch multiple comparisons test relative to DMSO control treated condition. **(e)** Correlation plot of RXRα LBD TR-FRET data vs. Nurr1-RXRα cellular transcription data. **(f)** Correlation plot of RXRα transcriptional reporter data vs. Nurr1-RXRα cellular transcription data. **(g)** Correlation plot of RXRα transcriptional reporter data vs. RXRα LBD TR-FRET data. Pearson (r_p) and Spearman (r_s) correlation coefficients and statistical significance testing are reported above the correlation plots.

The online version of this article includes the following source data for figure 4:

Source data 1. Retinoid X receptor alpha (RXRα) ligand treated RXRα ligand-binding domain (LBD) time-resolved fluorescence resonance energy transfer (TR-FRET) coactivator interaction data.

Source data 2. Retinoid X receptor alpha (RXRα) ligand treated RXRα/3xDR1-luciferase reporter data.

correlation was observed between coactivator peptide recruitment to the RXRα LBD and Nurr1-RXRα transcription for the RXRα ligand set (**Figure 4e**). Furthermore, no significant correlation is observed between RXRα homodimer transcription and Nurr1-RXRα transcription (**Figure 4f**). In contrast, a strong correlation is observed between RXRα LBD TR-FRET data and full-length RXRα transcription (**Figure 4g**) where ligands that increase PGC-1α coactivator peptide interaction to the RXRα LBD activate transcription of full-length RXRα in cells, similar to what we observed for PPARγ agonists with graded agonist transcriptional activity (**Shang et al., 2019**).

The two selective Nurr1-RXR α activating compounds, BRF110 and HX600, function as a pharmacological antagonist and weak/partial graded agonist in the RXR α homodimer TR-FRET and transcriptional reporter assay, respectively. These findings suggest that the mechanism by which the RXR α ligand set influences Nurr1-RXR α transcription may occur independent of coregulator recruitment to the RXR α LBD and RXR α -mediated transcription—indicating that ligand-dependent RXR α homodimer modulation and Nurr1-RXR α heterodimer modulation may function through distinct mechanisms.

Nurr1-RXR α activation is correlated with weakening LBD heterodimer affinity

Although ligand binding to NRs typically influences coregulator interaction to the AF-2 surface in the LBD, studies have reported that ligand binding can also weaken or strengthen NR LBD




Figure 5. Compound profiling for effects on Nurr1-retinoid X receptor alpha (RXR α) ligand-binding domain (LBD) heterodimer affinity and correlation to Nurr1-RXR α agonism. **(a)** General scheme of the Nurr1-RXR α LBD isothermal titration calorimetry (ITC) experiment. **(b)** Nurr1-RXR α LBD heterodimer affinities (log M) in the presence of DMSO (dotted line) or compound determined from the fit of the ITC data ($n=2$ replicates, except $n=1$ for IRX4204 and PA452) and represent the mean $\pm$ s.d.; see **Table 1** and **Figure 5—source data 1** for data plotted. Statistical testing was performed and p -values were calculated using ordinary one-way ANOVA relative to DMSO control treated condition. **(c)** Correlation plot of ITC determined Nurr1-RXR α LBD heterodimer K_D log M values vs. Nurr1-RXR α cellular transcription data. **(d)** Correlation plot of ITC determined Nurr1-RXR α LBD heterodimer K_D log M values vs. fitted binding enthalpy (ΔH , which is the ΔH_{AB} component of the homodimer competition model; see Materials and methods section for details). **(e)** Correlation plot of ITC determined Nurr1-RXR α LBD heterodimer K_D log M values vs. calculated binding entropy ($T\Delta S$). Pearson (r_p) and Spearman (r_s) correlation coefficients and statistical significance testing are reported above the correlation plot.

The online version of this article includes the following source data for figure 5:

Source data 1. Raw isothermal titration calorimetry (ITC) thermograms and fitted data.

homodimerization and heterodimerization and confer selectivity (Kilu et al., 2021; Powell and Xu, 2008; Rehó et al., 2020; Tamrazi et al., 2002). To determine how the RXR α ligand set influences Nurr1-RXR α LBD heterodimerization affinity, we performed isothermal titration calorimetry (ITC) studies where we titrated Nurr1 LBD into apo/ligand-free or ligand-bound RXR α LBD (Figure 5a) and fitted the data to a homodimer competition model that incorporates apo-RXR α LBD homodimerization affinity (see Materials and methods) and dissociation of RXR α LBD homodimers to obtain Nurr1-RXR α LBD heterodimerization affinity (Table 1 and Figure 5b). One limitation of this ITC data analysis is the assumption that the RXR α LBD homodimer affinity is the same for apo RXR α LBD and the various ligand-bound states. Determining ligand-bound RXR α LBD homodimer K_D values using ITC via the dimer dissociation dilution (McPhail and Cooper, 1997) would likely be confounded by ligand dissociation. It is also possible that RXR α ligands could change RXR α LBD homodimer affinity, or potentially change the RXR α LBD dimer equilibrium toward a tetrameric form where the Nurr1 LBD ITC titration could include a component that dissociates a ligand-bound RXR α LBD homotetramer (Chen et al., 1998; Gampe et al., 2000; Zhang et al., 2011a). Despite these limitations, a significant correlation between Nurr1-RXR α LBD heterodimerization affinity and Nurr1-RXR α transcription where RXR α ligands that weaken heterodimerization affinity show higher Nurr1-RXR α transcription (Figure 5c).

To gain additional insight into the thermodynamic mechanism of ligand-induced Nurr1-RXR α LBD heterodimer dissociation, we analyzed the thermodynamic parameters from the fitted ITC data (Table 1). The change in binding enthalpy (ΔH) upon heterodimerization generally shows an endothermic (positive) profile for all conditions, whereas the change in entropy (ΔS) component shows a favorable (positive) profile for all conditions. Correlation analysis reveals a more significant correlation between the Nurr1-RXR α LBD heterodimerization binding affinity and the ΔH binding component (Figure 5d) compared to the ΔS binding component (Figure 5e). Moreover, compounds that decrease Nurr1-RXR α LBD heterodimer binding affinity show an increasing (less favorable) ΔH component and an increasing (more favorable) ΔS component.

Nurr1-RXR α activation is correlated with dissociation of Nurr1 LBD monomer

To obtain structural insight into the consequence of ligand-induced weakening of Nurr1-RXR α LBD heterodimer and the relationship to transcriptional activation of Nurr1-RXR α , we performed protein NMR structural footprinting analysis. We collected 2D [^1H , ^{15}N]-TROSY-HSQC NMR data of ^{15}N -labeled Nurr1 LBD in the monomer form or heterodimerized with RXR α LBD. Among the well-resolved Nurr1 LBD peaks in the 2D NMR data that show clear and discernible shifts going from monomeric Nurr1 LBD to the Nurr1-RXR α LBD heterodimer (Figure 6—figure supplement 1) include the NMR peak for Thr411 (Figure 6a). Addition of compounds that activate Nurr1-RXR α transcription and weaken Nurr1-RXR α LBD heterodimer affinity result in the appearance of two Thr411 NMR peaks with chemical shift values corresponding to the heterodimer and Nurr1 monomer populations. In contrast, compounds that display little to no effect on Nurr1-RXR α transcription and do not significantly alter Nurr1-RXR α LBD heterodimer affinity show either a single NMR peak corresponding to the heterodimer population or a lower Nurr1 monomer population on average. These data indicate that Nurr1-RXR α activating ligands perturb the Nurr1-RXR α LBD heterodimer conformational ensemble toward a monomeric Nurr1 LBD population in slow exchange on the NMR time scale.

To gain additional insight into how ligand-dependent changes in Nurr1-RXR α LBD heterodimerization affinity influences the NMR data, we performed NMR lineshape simulations. Simulated 1D spectra of the $^1\text{H}_\text{N}$ dimension of the Thr411 NMR peaks were calculated using a binding model that accounts for an RXR α LBD homodimer component that dissociates into monomers that are capable of binding Nurr1 LBD (see Materials and methods for details). The simulations show that weakening Nurr1-RXR α LBD heterodimerization affinity, for example upon binding an RXR α ligand, shifts the equilibrium from the Nurr1-RXR α LBD heterodimeric (*hd*) population to Nurr1 LBD monomer (*m*) population (Figure 6b), consistent with our experimentally collected 2D NMR data.

We calculated the relative population of monomeric Nurr1 LBD dissociated from the Nurr1-RXR α LBD heterodimer by measuring the peak intensity of the monomeric (*m*) and heterodimer (*hd*) 2D NMR peaks for Thr411 from two replicate measurements using different batches of protein (Figure 6c). One limitation of this NMR analysis is that the monomeric and heterodimeric NMR peak intensities may over- or underestimate the relative population sizes given that NMR peak lineshapes

Table 1. Fitted and calculated isothermal titration calorimetry (ITC) Nurr1-RXRα binding affinity and thermodynamic parameters.

Ligand	log KD (M)				ΔH (kcal/mol)				TΔS (kcal/mol)			
	Average	s.d.	n	Replicates	Average	s.d.	n	Replicates	Average	s.d.	n	Replicates
DMSO	-5.335	0.118	2	-5.418	-5.252	0.240	2	3.070	2.730	0.401	2	10.462
BRF110	-4.376	0.020	2	-4.390	-4.362	0.361	2	5.110	5.620	0.334	2	11.099
HX600	-4.662	0.028	2	-4.681	-4.642	4.320	2	4.640	10.750	4.283	2	11.026
9cRA	-5.026	0.060	2	-4.984	-5.068	0.962	2	5.790	4.430	3.105	2	12.589
Bexarotene	-4.619	0.044	2	-4.588	-4.650	1.336	2	4.610	6.500	1.396	2	10.870
LG100268	-5.044	0.106	2	-5.119	-4.969	0.148	2	5.240	5.030	0.294	2	12.224
CD3254	-4.860	0.099	2	-4.930	-4.790	0.389	2	5.140	4.590	0.524	2	11.866
SR11237	-5.053	0.047	2	-5.087	-5.020	0.962	2	5.620	4.260	1.026	2	12.560
UVI3003	-4.565	0.021	2	-4.580	-4.550	2.638	2	7.990	4.260	2.666	2	14.238
LG100754	-5.222	0.026	2	-5.204	-5.240	0.226	2	4.110	4.430	0.261	2	11.209
IRX4204	-4.673	0.000	1	-4.673		0.000	1	8.460		0.000	1	14.835
Rhein	-5.554	0.077	2	-5.499	-5.609	0.396	2	3.060	2.500	0.290	2	10.563
HX531	-6.132	0.133	2	-6.226	-6.038	0.021	2	2.190	2.220	0.160	2	10.684
Danthron	-5.524	0.043	2	-5.494	-5.554	0.170	2	3.040	2.800	0.111	2	10.535
PA452	-5.417	0.000	1	-5.417		0.000	1	4.120		0.000	1	11.510




Figure 6. Compound profiling for effects on Nurr1-retinoid X receptor alpha (RXR α) ligand-binding domain (LBD) conformational properties in solution and correlation to Nurr1-RXR α agonism. (a) 2D ^1H , ^{15}N -TROSY HSQC data of ^{15}N -labeled Nurr1 LBD heterodimerized with unlabeled RXR α LBD in the presence of RXR α ligands focused on the NMR peak of Thr411. The upper inset shows an overlay of ^{15}N -labeled Nurr1 LBD monomer (200 μM) vs. ^{15}N -labeled Nurr1 LBD-unlabeled RXR α LBD heterodimer (1:2 molar ratio) to demonstrate the shift of the Thr411 peak between monomer (m) and heterodimer (hd) forms; see **Figure 6—figure supplement 1** for full spectral overlays. (b) Simulated ^1H NMR lineshape analysis of Nurr1 LBD residue Thr411 showing the influence of ligand-induced weakening of Nurr1-RXR α LBD heterodimerization affinity; see **Figure 6—source code 1** for

Figure 6 continued on next page

Figure 6 continued

calculation input files. (c) NMR estimated Nurr1 LBD monomer populations from the 2D NMR data (n=2 replicates, except n=1 for IRX4204 and PA452) and lines above the replicate values represent the mean $\pm$ s.d.; see **Figure 6—source data 1** for data plotted. Statistical testing was performed and p-values were calculated using ordinary one-way ANOVA relative to apo/DMSO control treated condition. (d) Correlation plot of Nurr1-RXR α cellular transcription data vs. NMR estimated Nurr1 LBD monomer populations. (e) Correlation plot of ITC determined Nurr1-RXR α LBD heterodimer K_D log M values vs. NMR estimated Nurr1 LBD monomer populations. Pearson (r_p) and Spearman (r_s) correlation coefficients and statistical significance testing are reported above the correlation plots. (f) Analytical size exclusion chromatography (SEC) analysis of Nurr1-RXR α in the presence of RXR α ligands (solid colored lines) relative to Nurr1 LBD monomer (dotted black line) and Nurr1-RXR α LBD heterodimer (solid black line); see **Figure 6—figure supplement 2** for all SEC data organized by ligand.

The online version of this article includes the following source data, source code, and figure supplement(s) for figure 6:

Source code 1. Input files for NMR LineShapeKin simulated NMR data analysis in MATLAB (two input files and one readme file).

Source data 1. Retinoid X receptor alpha (RXR α) ligand treated Nurr1-RXR α ligand-binding domain (LBD) NMR-observed monomer species.

Figure supplement 1. Full overlay of 2D [^1H , ^{15}N]-TROSY-HSQC data of ^{15}N -labeled Nurr1 ligand-binding domain (LBD) (200 μM) in monomeric (m) and heterodimer (hd) forms with retinoid X receptor alpha (RXR α) LBD (400 μM).

Figure supplement 2. Analytical size exclusion chromatography (SEC) profiles of Nurr1 ligand-binding domain (LBD) (monomer), retinoid X receptor alpha (RXR α) LBD (homodimer and homotetramer), and Nurr1-RXR α LBD (heterodimer) with RXR α ligands present in the RXR α LBD-containing conditions (homodimer or Nurr1-RXR α heterodimer).

Figure supplement 3. SDS-PAGE analysis of fractions collected from size exclusion chromatography (SEC) analysis of Nurr1-retinoid X receptor alpha (RXR α) ligand-binding domain (LBD) heterodimer in the presence of BRF110.

Figure supplement 3—source data 1. Full raw unedited gel, without and with annotation (two JPG files).

of the individual monomeric and heterodimer states (molecular sizes effects), and the rate of chemical exchange between these states, can also affect peak lineshapes as well as binding kinetics and affinity. Despite this limitation, a significant correlation is observed between NMR-observed Nurr1 LBD monomeric populations and Nurr1-RXR α transcription (**Figure 6d**) and ITC-determined Nurr1-RXR α LBD heterodimerization affinity (**Figure 6e**), indicating a role for dissociation of monomeric Nurr1 LBD from Nurr1-RXR α LBD heterodimer in the mechanism of action of the RXR α ligand set. Notably, one of the replicate NMR measurements shows a more significant correlation to Nurr1-RXR α transcription, which may have at least two origins: errors in concentration between two different batches of protein used in the replicate measurements, and two ligands were not included in one of the replicate measurements—excluding these ligands from the analysis of replicate #2 measurements improves the correlation with $r_p = 0.77$ ($p=0.0021$) and $r_s = 0.75$ ($p=0.0042$).

To corroborate our ligand-dependent heterodimer dissociation findings, we performed size exclusion chromatography (SEC) experiments to determine how the compounds influence the oligomeric state of the Nurr1-RXR α LBD heterodimer (**Figure 6g** and **Figure 6—figure supplement 2**). The Nurr1-RXR α selective agonist, BRF110, shows the largest effect in dissociating a Nurr1 LBD monomer species in the SEC and NMR studies and is overall the most efficacious compound in activating Nurr1-RXR α transcription. The other Nurr1-RXR α selective compound, HX600, and the classical RXR α agonists dissociate a Nurr1 LBD monomer species although to a lower degree compared to BRF110. Most pharmacological RXR α antagonists we studied do not dissociate a Nurr1 LBD monomer species except for UVI3003, which displays a unique SEC profile that includes a monomeric Nurr1 LBD species and at least two species with a larger hydrodynamic radius (**Figure 6—figure supplement 2**). One higher order species is consistent with the SEC profile of an RXR α LBD homodimer or Nurr1-RXR α LBD heterodimer, and another with a larger hydrodynamic radius that is more compact than RXR α homotetramer, suggesting it may be a UVI3003-bound RXR α LBD dimer population. Notably, our structure-function profiling data indicate UVI3003 functions similar to the Nurr1-RXR α selective ligands (BRF110 and HX600) in that it activates Nurr1-RXR α transcription while antagonizing RXR α homodimers.

The SEC data provide insight into the potential allosteric mechanism(s) by which compounds in the RXR α ligand set influence Nurr1-RXR α heterodimerization and transcription via effects on RXR α LBD. In the absence of ligand, RXR α exists as a mixture of homodimers and homotetramers (Kersten et al., 1995a), which can be stabilized as dimers upon agonist binding (Kersten et al., 1995b) or tetramers upon antagonist binding (Zhang et al., 2011b). In our SEC data, the most efficacious compounds not only free a Nurr1 LBD monomeric population, but also increase a higher order species with an elution volume consistent with a RXR α LBD homotetramer population. SDS-PAGE analysis confirms this observation and reveals that the higher order species observed when BRF110 is added to Nurr1-RXR α




Figure 7. Principal component analysis (PCA) of experimental data reveals Nurr1-retinoid X receptor alpha (RXR α) agonism and classical RXR α agonism are uncorrelated. **(a)** 2D biplot containing the loadings and PC scores of the first two PCs. PC scores of the ligands are colored according to pharmacological activity (see legend) whereas the loadings (experimental variables) are colored light blue. **(b)** A proportion of variance plot revealing the amount of variance described by each PC individually and cumulatively.

LBD heterodimers contains RXR α LBD only (**Figure 6—figure supplement 3**). Furthermore, these compounds change the appearance of species in the SEC data with elution properties similar to Nurr1-RXR α heterodimer and RXR α homodimers, suggesting that they may change the homodimer/heterodimer complex conformation and/or species equilibrium. Thus, the allosteric mechanism may involve ligand-induced stabilization of RXR α oligomeric species that inhibit or are less favorable for Nurr1 heterodimerization.

PCA reveals data features associated with Nurr1-RXR α agonism

Finally, we performed principal component analysis (PCA) using all the experimental data collected as input to determine the data features most associated with transcriptional activation of the 3xNBRE-luciferase reporter by Nurr1-RXR α in an unbiased manner (**Figure 7a**). Two of the ligands, danthron and rhein, were not included in the analysis because we did not have RXR α LBD TR-FRET and RXR α homodimer transcriptional reporter data (vide infra). Approximately 90% of the variance in the data can be explained by the two PCs (**Figure 7b**). Several features are notable in the plot of the PCA scores and loadings, the latter of which represent correlation between the experimental data and PCs. The ligands cluster in groups consistent with their known pharmacological phenotypes. The loadings show that Nurr1-RXR α transcription, ITC-determined Nurr1-RXR α heterodimer affinity, and NMR-determined Nurr1 monomeric populations are clustered together and clustered along with the Nurr1-RXR α selective ligands, meaning these features of the data are positively correlated with ligand-dependent Nurr1-RXR α heterodimer dissociation. In contrast, RXR α LBD TR-FRET coactivator interaction and RXR α LBD homodimer transcription is positively correlated with classical RXR α agonists, whereas RXR α antagonists are found opposite to this loading trajectory. Furthermore, the loading projections show that the features of classical RXR α agonism and selective Nurr1-RXR α agonism are uncorrelated since the loadings trajectories associated with these features, and their associated ligand clusters, form a perpendicular ($\sim 90^\circ$) angle.

Discussion

Although Nurr1 is a promising drug target for aging-associated neurodegenerative disorders, uncertainty in the druggability of its LBD has motivated research into alternative approaches to influence Nurr1 transcription. Nurr1-RXR α heterodimer activation via RXR α -binding ligands has emerged as a promising modality to develop neuroprotective therapeutic agents or adjuvants to other therapies. Several RXR α ligands that increase Nurr1-RXR α activation have progressed to clinical trials of PD and AD including bexarotene and IRX4204 (**McFarland et al., 2013; Wang et al., 2016**). Understanding how these and other Nurr1-RXR α activating ligands function on the molecular level may provide a blueprint to develop more efficacious and potent compounds.




Figure 8. Data-informed model for activation of Nurr1-retinoid X receptor alpha (RXR α) transcription by RXR α ligands.

Classical pharmacological modulation of NR transcription by agonists, antagonists, or inverse agonists that activate, block, or repress transcription typically function by enhancing coactivator protein interaction, blocking coregulator interaction, or enhancing corepressor interaction, respectively (*Gronemeyer et al., 2004*). Our studies demonstrate that Nurr1-RXR α activation occurs through an LBD PPI inhibition heterodimer dissociation mechanism that is distinct from the classical pharmacological properties of NRs ligands. This activation mechanism explains why pharmacological RXR α agonists (e.g. bexarotene and IRX4204) and Nurr1-RXR α selective compounds that function as pharmacological RXR α antagonists (e.g. BRF110 and HX600) both activate Nurr1-RXR α transcription. Although the LBD heterodimer dissociation mechanism is atypical, several studies have reported that pharmacological NR ligands can influence dimer formation in addition to their classical pharmacological properties in regulating coregulator protein interaction (*Kilu et al., 2021; Powell and Xu, 2008; Rehó et al., 2020; Tamrazi et al., 2002*). Our Nurr1-RXR α LBD heterodimer dissociation findings add to the repertoire of functional ligand targeting mechanisms of NRs that include classical pharmacological ligands, ligand-modulated posttranslational modification (*Choi et al., 2011*), PROTAC degrader molecules (*Flanagan and Neklesa, 2019*), and ligand-modulated NR phase separation/biomolecular condensates that include covalent targeting of the disordered N-terminal AF-1 domain (*Basu et al., 2022; Xie et al., 2022*).

Our data in support of a Nurr1-RXR α LBD heterodimer dissociation activation mechanism along with other published studies inform a model for activation of Nurr1-RXR α transcription by RXR α ligands (**Figure 8**). Nurr1 displays high transcriptional activity on monomeric NBRE sites as a monomer, and RXR α heterodimerization represses Nurr1 activity (*Aarnisalo et al., 2002; Forman et al., 1995*). RXR α does not bind to NBRE sequences but does interact with Nurr1 bound to NBRE DNA sequences via a protein-protein tethering interaction (*Sacchetti et al., 2002*) and recruits corepressor proteins that are released upon binding RXR α ligand (*Lammi et al., 2008*). Our RXR α truncation studies indicate that RXR α represses Nurr1 transcription through an RXR α LBD-dependent mechanism, pinpointing the Nurr1 and RXR α LBDs as the likely mode of tethering. Pharmacological agonists of RXR α , which stabilize an active RXR α LBD conformation (*De Lera et al., 2007*), as well as Nurr1-RXR α selective compounds (*Morita et al., 2005; Spathis et al., 2017*) that function as pharmacological antagonists of RXR α , dissociate tethered Nurr1-RXR α heterodimers leaving a monomeric Nurr1 bound to monomeric NBRE sites that has higher transcriptional activity than Nurr1-RXR α .

In contrast to the ligand-induced heterodimer dissociation activation mechanism, ligands that stabilize/strengthen Nurr1-RXR α heterodimerization or do not significantly affect Nurr1-RXR α dissociation—such as the RXR α antagonists in our study—may show more complex regulatory mechanisms. In addition to influencing Nurr1-RXR α interaction, antagonist ligands bound to RXR α , which is itself tethered to Nurr1 on NBRE genomic elements, could influence transcription of NBRE-driven gene transcription via classical pharmacological modulation mechanisms. RXR α -bound ligands will influence the conformation of and coregulator protein binding affinity to the RXR α AF-2 surface, which will in turn regulate recruitment of coregulator (coactivator or corepressor) proteins via interaction with the RXR α AF-2 surface.

In summary, our study shows that RXR α ligands can function as allosteric PPI inhibitors that bind to the canonical orthosteric ligand-binding pocket within the RXR α LBD and influence and Nurr1-mediated transcription via Nurr1-RXR α heterodimer dissociation. Our findings provide a molecular

understanding into the mechanism of action of Nurr1-RXR α activation that may influence the design and development of new compounds with therapeutic efficacy in PD, AD, and other aging-associated neurodegenerative disorders.

Materials and methods

Ligands, plasmids, and other reagents

All ligands were obtained from commercial vendors including Cayman Chemicals, Sigma, Axon Medchem, MedChemExpress, or Tocris Bioscience; BRF110 (CAS 2095489-35-1), HX600 (CAS 172705-89-4), 9cRA (CAS 5300-03-8), Bexarotene (CAS 153559-49-0), LG100268 (CAS 153559-76-3), CD3254 (CAS 196961-43-0), SR11237 (CAS 146670-40-8), UVI3003 (CAS 847239-17-2), LG100754 (CAS 180713-37-5), IRX4204 (CAS 220619-73-8), Rhein (CAS 478-43-3), HX531 (CAS 188844-34-0), Danthron (CAS 117-10-2), and PA452 (CAS 457657-34-0). FITC-labeled LXXLL-containing peptide derived from human PGC-1 α (137-155; EAEEPSLLKLLAPANTQ) was synthesized by LifeTein with an N-terminal FITC label and an amidated C-terminus for stability. Bacterial expression plasmids included human Nurr1 (NR4A2) LBD (residues 353–598) (*de Vera et al., 2016*) and human RXR α (NR2B1) LBD (residues 223–462) (*Kojetin et al., 2015*) that were inserted into a pET45b(+) plasmid (Novagen) as a TEV-cleavable N-terminal hexahistidine(6xHis)-tag fusion protein. Luciferase reporter plasmids included a 3xNBRE-luciferase plasmid containing three copies of the NGFI-B response element corresponding to the monomeric binding site for Nurr1 (*de Vera et al., 2016; Wilson et al., 1991*); and a 3xDR1-luciferase containing three copies of the optimal direct repeat 1 (DR1) binding site for RXR α (*Hughes et al., 2014; Subauste et al., 1994*). Mammalian expression plasmids included full-length human Nurr1 (residues 1–598) in pcDNA3.1 plasmid (*de Vera et al., 2016*) and full-length human RXR α (residues 1–462) in pCMV-Sport6 plasmid (*Zhang et al., 2011c*). To clone the RXR α Δ LBD construct (residues 1–226), site directed mutagenesis and PCR was used to insert a stop codon before the start of the LBD using the full-length RXR α expression plasmid the following primers: forward primer, CAGCAGCGCCTAAGAGGACATG; reverse primer, CATGTCCTCTTAGGCGCTGCTG. To clone the Δ NTD RXR α construct (residues 127–462), site directed mutagenesis and PCR was used to add a XhoI cut site and an ATG before at the end of the NTD using the following primers: forward primer, CCACCCCTCGAGAAACATGG; reverse primer, CCATGTTTCTCGAGGGGTGG—then restriction enzymes (XhoI and HindIII) were used to cut out the Δ NTD construct (DBD-hinge-LBD) for insertion using T4 ligase into pcDNA3.1 empty vector that had been linearized with XhoI and HindIII. To clone the RXR α LBD construct (200–462), XhoI was used to cut pcDNA3.1 and subsequently Gibson assembly was used to clone the LBD into the linearized vector using the gBlock sequence provided in *Supplementary file 1*.

Cell lines for mammalian cell culture

All cells were obtained from and authenticated by ATCC and determined to be mycoplasma free. HEK293T (#CRL-11268) and SK-N-BE(2)-C (#CRL-2268) cells were cultured according to ATCC guidelines at low passage number (less than 10 passages; typically passages 2–4). HEK293T cells were grown at 37°C and 5% CO₂ in DEME (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 100 units/mL of penicillin, 100 μ g/mL of streptomycin, and 0.292 mg/mL of glutamine (Gibco) until 90–95% confluence in T-75 flasks prior to subculture or use. SK-N-BE(2)-C were grown at 37°C and 5% CO₂ in a media containing 1:1 mixture of EMEM (ATCC) and F12 medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) until 90–95% confluence in T-75 flasks prior to subculture or use.

Protein expression and purification

Proteins were expressed in *Escherichia coli* BL21(DE3) cells in autoinduction ZY media (without NMR isotopes) or M9 minimal media (using ¹⁵NH₄Cl for NMR isotopic labeling). For autoinduction expression, cells were grown for 5 hr at 37°C, then 18 hr at 22°C, then centrifuged for harvesting. For M9 expression, cells were grown at 37°C and induced with 1.0 mM isopropyl β -D-thiogalactoside at OD (600 nm) of 0.6, grown for an additional 18 hr at 22°C, and then centrifuged for harvesting. Cell pellets were lysed using sonication and proteins were purified using Ni-NTA affinity chromatography and gel filtration/SEC. TEV protease was used to cleave the 6xHis-tag for all experiments except protein used for TR-FRET. The purified proteins were verified by SDS-PAGE, then stored in a buffer consisting of

20 mM potassium phosphate (pH 7.4), 50 mM potassium chloride, and 0.5 mM EDTA. All studies that used RXR α LBD protein used pooled SEC fractions for the apo-homodimeric form except for analytical SEC of the apo-tetrameric form.

Transcriptional reporter assays

SK-N-BE(2)-C cells were seeded in 9.5 cm² cell culture well (Corning) at 0.5 million for transfection using Lipofectamine 2000 (Thermo Fisher Scientific) and Opti-MEM with an empty vector control or full-length Nurr1 expression plasmid (1 μ g), with or without full-length or different RXR α truncation constructs (1 μ g), and 3xNBRE-luc (1 μ g). HEK293T cells were seeded in 9.5 cm² cell culture well (Corning) at 0.5 million for transfection using Lipofectamine 2000 (Thermo Fisher Scientific) and Opti-MEM with empty vector control or full-length RXR α expression plasmid (1 μ g), and 3xDR1-luc (1 μ g). After incubation for 16–20 hr, cells were transferred to white 384-well cell culture plates (Thermo Fisher Scientific) at 0.5 million cells/mL in 20 μ L total volume/well. After a 4 hr incubation, cells were treated with 20 μ L of vehicle control (DMSO) or 1 μ M ligand. After a final 16–20 hr incubation, cells were harvested with 20 μ L Britelite Plus (PerkinElmer), and luminescence was measured on a BioTek Synergy Neo multimode plate reader. The luminescence readouts were normalized to cells transfected with the empty vector (truncation construct assay) or cells treated with DMSO (assays with or without ligand treatment). Data were plotted using GraphPad Prism. In **Figure 1b**, statistical testing was performed and p-values were calculated in GraphPad Prism using the Brown-Forsythe and Welch multiple comparisons test (does not assume equal s.d. values among compared conditions) relative to full-length Nurr1 condition. In **Figures 3b and 4d**, statistical testing was performed and p-values were calculated in GraphPad Prism using the Brown-Forsythe and Welch multiple comparisons test (does not assume equal s.d. values among compared conditions) relative to DMSO control treated condition. Data are representative of two or more independent experiments (n=6 or 9 biological replicates).

TR-FRET coactivator interaction assay

Assays were performed in 384-well black plates (Greiner) using 22.5 μ L final well volume. Each well contained 4 nM 6xHis-RXR α LBD, 1 nM LanthaScreen Elite Tb-anti-His antibody (Thermo Fisher #PV5895), and 400 nM FITC-labeled PGC1 α peptide in a buffer containing 20 mM potassium phosphate (pH 7.4), 50 mM KCl, 5 mM TCEP, and 0.005% Tween 20. Ligand stocks were prepared via serial dilution in DMSO and added to wells (10 μ M final concentration) in triplicate. The plates were read using BioTek Synergy Neo multimode plate reader after incubation at 4°C for at least 2 hr. The Tb donor was excited at 340 nm, and its emission was measured at 495 nm; the emission of the acceptor FITC was measured at 520 nm. Data were plotted using GraphPad Prism as TR-FRET ratio (measurement at 520 nm/measurement at 495 nm) at a fixed ligand concentration (2–4 μ M depending on the starting compound stock concentration). In **Figure 4b**, statistical testing was performed and p-values were calculated in GraphPad Prism using the Brown-Forsythe and Welch multiple comparisons test (does not assume equal s.d. values among compared conditions) relative to the DMSO control treated condition. Data are representative of two or more independent experiments (n=3 biological replicates) except for one RXR α ligand (IRX4204) where only one experiment (n=3 biological replicates) was performed.

Isothermal titration calorimetry

Experiments were performed using a MicroCal iTC200. All experiments were solvent-matched and contained 0.25% DMSO (ligand vehicle) final concentration. RXR α LBD homodimerization affinity was measured using a dimer dissociation dilution method (**McPhail and Cooper, 1997**) by titrating 1 mM RXR α LBD from the syringe into the ITC buffer in the sample cell at 25°C with a 60 s delay between the 2 μ L injections using a mixing speed of 1200 rpm for a total of 20 injections. Data were fitted using the dissociation model in MicroCal Origin 6.0 (MicroCal User Manual, section 7.6). RXR α LBD homodimer affinity (K_D) and enthalpy were determined to be 16.3 μ M and –13.10 kcal/mol, respectively; this information was used in analysis of the interactions between Nurr1 LBD and ligand-bound RXR α LBD to approximate the dissociation step required for Nurr1 LBD to heterodimerize with RXR α LBD. ITC experiments of Nurr1 LBD to RXR α LBD (apo or ligand-bound) was performed by titrating Nurr1 LBD to RXR α LBD in a 10:1 ratio (500 or 1000 μ M, and 50 or 100 μ M, respectively) incubated with two equivalent of vehicle (DMSO) or ligand, and the run was performed using the same experimental

design. Experiments were performed at 25°C in duplicate, except for two RXR α ligands (IRX4204 and PA452) where only one experiment was performed; and one experimental replicate for HX600 was performed at 15°C, which gave a similar K_D value to the data collected at 25°C. NITPIC software (Keller *et al.*, 2012) was used to calculate baselines, integrate curves, prepare experimental data for fitting in SEDPHAT (Brautigam *et al.*, 2016), which was used to obtain binding affinities and thermodynamic parameter measurements using a homodimer competition model ($A + B + C \rightleftharpoons AB + C \rightleftharpoons AC + B$; competing B and C for A, where A and C is RXR α LBD monomer and B is Nurr1 LBD monomer). Final figures were exported using GUSI (Brautigam, 2015). In **Figure 5b**, statistical testing was performed and p-values were calculated in GraphPad Prism using ordinary one-way ANOVA relative to DMSO control treated condition.

NMR spectroscopy

Two-dimensional [^1H , ^{15}N]-TROSY-HSQC NMR experiments were performed at 298 K on a Bruker 700 MHz NMR instrument equipped with a QCI cryoprobe. Samples were prepared in a buffer containing 20 mM potassium phosphate (pH 7.4), 50 mM potassium chloride, 0.5 mM EDTA, and 10% D_2O . Experiments were collected using 200 μM ^{15}N -labeled Nurr1 LBD with or without two molar equivalents of unlabeled RXR α LBD in the absence or presence of RXR α ligands. Data were processed and analyzed using NMRfX (Norris *et al.*, 2016) using published NMR chemical shift assignments for the Nurr1 LBD (Michiels *et al.*, 2010) that we validated and used previously (de Vera *et al.*, 2019; Munoz-Tello *et al.*, 2020). Relative Nurr1 LBD monomer populations were estimated by the relative peak intensities of the monomeric (I_{monomer}) and heterodimer ($I_{\text{heterodimer}}$) species using the following equation:

$$I_{\text{monomer_population}} = \frac{I_{\text{monomer}}}{I_{\text{monomer}} + I_{\text{heterodimer}}}$$

NMR peak intensity errors for the monomeric (E_{monomer}) and heterodimeric ($E_{\text{heterodimer}}$) states were calculated in NMRfX and propagated in the $I_{\text{monomer_population}}$ calculation using the following equation:

$$E_{\text{monomer_population}} = \sqrt{\left(\frac{I_{\text{monomer}}}{(I_{\text{heterodimer}} + I_{\text{monomer}})^2}\right)^2 + \left(-\frac{I_{\text{heterodimer}}}{(I_{\text{monomer}} + I_{\text{heterodimer}})^2}\right)^2}$$

Two replicates per condition were performed, except for two RXR α ligands (IRX4204 and PA452) where only one experiment was performed; average and s.d. calculations of the replicate $I_{\text{monomer_population}}$ and $E_{\text{monomer_population}}$ were performed in GraphPad Prism. In **Figure 6c**, statistical testing was performed and p-values were calculated in GraphPad Prism using ordinary one-way ANOVA relative to apo/DMSO control treated condition. We distinguished the two replicate measurements in the analysis, which were performed using different protein and ligand stock solutions, because one batch of samples (replicate 1) showed a more significant correlation to transcription than the other batch of samples.

NMR lineshape simulations

NMR lineshape analysis was performed using NMR LineShapeKin version 4 (Kovrigin, 2012) and MATLAB R2022a via NMRbox (Maciejewski *et al.*, 2017). 1D NMR lineshapes for Nurr1 LBD residue T411 ($^1\text{H}_\text{N}$ dimension), with or without two molar equivalents of RXR α LBD, were simulated using the U_L2 model (ligand binding to a receptor competing with ligand dimerization) where the ligand (RXR α LBD) exists as a homodimer that is dissociated into monomers upon binding to the receptor (^{15}N -labeled Nurr1 LBD). Simulations were performed using several experimentally defined parameters: ITC-determined apo-RXR α LBD homodimer affinity (16 μM); difference in chemical shift in hertz (150 Hz) between the monomer and heterodimer NMR peaks for T411 measured in 2D [^1H , ^{15}N]-TROSY HSQC NMR data (w_0 for R = -150 Hz; w_0 for RL = 0 Hz); a receptor concentration of 200 μM ($R_{\text{total}} = 2e-3$); and ligand added at ± 2 molar equivalents ($LR_{\text{ratio}} = 1e-3$ and 2.0); and relative relaxation rates for the monomer and heterodimer estimated to give peak full width half height (FWHH) line widths in 2D [^1H , ^{15}N]-TROSY HSQC NMR data (for R, FWHH = 20, $R_2 = 10$; for RL, FWHH = 40, $R_2 = 20$ Hz); otherwise default parameters were used.

Analytical SEC

To prepare Nurr1-RXR α LBD heterodimer for analytical SEC analysis, purified Nurr1 LBD and RXR α LBD (each 700 μ M in 2.5 mL) were incubated together at 4°C in their storage buffer containing 20 mM potassium phosphate (pH 7.4), 50 mM potassium chloride, and 0.5 mM EDTA for 16 hr, injected (5 mL total) into HiLoad 16/600 Superdex 75 pg (Cytiva) connected to an AKTA FPLC system (GE Healthcare Life Science). Gel filtration was performed using the same buffer to purify Nurr1-RXR α LBD heterodimer for analysis, collecting 2 mL fraction to isolate heterodimer population into 15 samples of 0.5 mL (at a protein concentration of 300 μ M) for analytical gel filtration. Additionally, purified Nurr1 LBD and RXR α LBD (pooled gel filtration fractions consisting of the homodimeric and homotetrameric species) were also used. Samples containing RXR α LBD (homodimer or heterodimer with Nurr1 LBD) were incubated with two molar equivalents of each ligand for 16 hr at 4°C before injection onto Superdex 75 Increase 10/300 GL (Cytiva) connected to the same AKTA FPLC system. The UV chromatograms were exported in CSV format and plotted using an in-house Jupyter notebook Python script using matplotlib and seaborn packages.

Correlation and other statistical analyses

Correlation plots were performed using GraphPad Prism to calculate Pearson (r_p) and Spearman (r_s) correlation coefficients and two-tailed p-values between two experimental measurements per plot. Statistical testing of control to variable conditions was performed using one-way ANOVA testing as detailed above. PCA was performed in GraphPad Prism; all experimentally determined data were used as variables (method = standardize, PCs selected based on parallel analysis at the 95% percentile level with 1000 simulations). p-Value statistical significance shorthand conforms to GraphPad Prism standards: n.s., $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$; and ****, $p \leq 0.0001$.

Acknowledgements

This work was supported by National Institutes of Health (NIH) grant R01AG070719 from the National Institute on Aging (NIA).

Additional information

Funding

Funder	Grant reference number	Author
National Institute on Aging	R01AG070719	Douglas J Kojetin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Xiaoyu Yu, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing; Jinsai Shang, Data curation, Formal analysis, Validation, Investigation, Writing – review and editing; Douglas J Kojetin, Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing

Author ORCIDs

Xiaoyu Yu  <http://orcid.org/0000-0003-0549-9560>

Douglas J Kojetin  <http://orcid.org/0000-0001-8058-6168>

Decision letter and Author response

Decision letter <https://doi.org/10.7554/eLife.85039.sa1>

Author response <https://doi.org/10.7554/eLife.85039.sa2>

Additional files

Supplementary files

Supplementary file 1. gBlock sequence used to clone the retinoid X receptor alpha (RXR α) ligand-binding domain (LBD) only construct.

MDAR checklist

Data availability

Raw ITC thermograms and fitted data are provided as Figure 5-source data 1. Input files for NMR LineShapeKin simulated NMR data analysis in MATLAB are provided as Figure 6-source code 1 (zip file including two input files and one readme file). Raw data used for graphical plots are provided as Figure 1-source data 1 (Nurr1 + RXR α truncated construct luciferase reporter data), Figure 3-source data 1 (RXR α ligand treated Nurr1-RXR α /3xNBRE3-luciferase reporter data), Figure 4-source data 1 (RXR α ligand treated RXR α LBD TR-FRET), Figure 4-source data 2 (RXR α ligand treated RXR α /3xDR1-luciferase reporter data), and Figure 6-source data 1 (RXR α ligand treated Nurr1-RXR α LBD NMR-observed monomer species). All other data generated or analyzed during this study are included in the manuscript and supporting files.

References

- Aarnisalo P, Kim CH, Lee JW, Perlmann T. 2002. Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1. *The Journal of Biological Chemistry* **277**:35118–35123. DOI: <https://doi.org/10.1074/jbc.M201707200>, PMID: 12130634
- Basu S, Martínez-Cristóbal P, Pesarrodon M, Frigolé-Vivas M, Szulc E, Lewis M, Adriana Bañuelos C, Sánchez-Zarzalejo C, Bielskutė S, Zhu J, García-Cabau C, Batlle C, Mateos B, Biesaga M, Escobedo A, Bardia L, Verdaguer X, Ruffoni A, Mawji NR, Wang J, et al. 2022. androgen receptor condensates as drug targets. [bioRxiv]. DOI: <https://doi.org/10.1101/2022.08.18.504385>
- Brautigam CA. 2015. Calculations and publication-quality illustrations for analytical ultracentrifugation data. *Methods in Enzymology* **562**:109–133. DOI: <https://doi.org/10.1016/bs.mie.2015.05.001>, PMID: 26412649
- Brautigam CA, Zhao H, Vargas C, Keller S, Schuck P. 2016. Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions. *Nature Protocols* **11**:882–894. DOI: <https://doi.org/10.1038/nprot.2016.044>, PMID: 27055097
- Bruning JM, Wang Y, Oltrabella F, Tian B, Kholodar SA, Liu H, Bhattacharya P, Guo S, Holton JM, Fletterick RJ, Jacobson MP, England PM. 2019. Covalent modification and regulation of the nuclear receptor Nurr1 by a dopamine metabolite. *Cell Chemical Biology* **26**:674–685. DOI: <https://doi.org/10.1016/j.chembiol.2019.02.002>, PMID: 30853418
- Chen ZP, Iyer J, Bourguet W, Held P, Mioskowski C, Lebeau L, Noy N, Chambon P, Gronemeyer H. 1998. Ligand- and DNA-induced dissociation of RXR tetramers. *Journal of Molecular Biology* **275**:55–65. DOI: <https://doi.org/10.1006/jmbi.1997.1413>, PMID: 9451439
- Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidović D, Shulman GI, Spiegelman BM, Griffin PR. 2011. Antidiabetic actions of a non-agonist PPAR γ ligand blocking cdk5-mediated phosphorylation. *Nature* **477**:477–481. DOI: <https://doi.org/10.1038/nature10383>, PMID: 21892191
- Decressac M, Volakakis N, Björklund A, Perlmann T. 2013. Nurr1 in Parkinson disease -- from pathogenesis to therapeutic potential. *Nature Reviews. Neurology* **9**:629–636. DOI: <https://doi.org/10.1038/nrneuro.2013.209>, PMID: 24126627
- De Lera AR, Bourguet W, Altucci L, Gronemeyer H. 2007. Design of selective nuclear receptor modulators: RAR and RXR as a case study. *Nature Reviews. Drug Discovery* **6**:811–820. DOI: <https://doi.org/10.1038/nrd2398>, PMID: 17906643
- Delerive P, Wu Y, Burris TP, Chin WW, Suen CS. 2002. Pgc-1 functions as a transcriptional coactivator for the retinoid X receptors. *Journal of Biological Chemistry* **277**:3913–3917. DOI: <https://doi.org/10.1074/jbc.M109409200>, PMID: 11714715
- de Vera IMS, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, Campbell S, Wilson HD, Granados J, Gardner WJ, Creamer TP, Solt LA, Kojetin DJ. 2016. Identification of a binding site for unsaturated fatty acids in the orphan nuclear receptor Nurr1. *ACS Chemical Biology* **11**:1795–1799. DOI: <https://doi.org/10.1021/acscchembio.6b00037>, PMID: 27128111
- de Vera IMS, Munoz-Tello P, Zheng J, Dharmarajan V, Marciano DP, Matta-Camacho E, Giri PK, Shang J, Hughes TS, Rance M, Griffin PR, Kojetin DJ. 2019. Defining a canonical ligand-binding pocket in the orphan nuclear receptor Nurr1. *Structure* **27**:66–77. DOI: <https://doi.org/10.1016/j.str.2018.10.002>, PMID: 30416039
- Flanagan JJ, Neklesa TK. 2019. Targeting nuclear receptors with PROTAC degraders. *Molecular and Cellular Endocrinology* **493**:110452. DOI: <https://doi.org/10.1016/j.mce.2019.110452>, PMID: 31125586
- Forman BM, Umesono K, Chen J, Evans RM. 1995. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. *Cell* **81**:541–550. DOI: [https://doi.org/10.1016/0092-8674\(95\)90075-6](https://doi.org/10.1016/0092-8674(95)90075-6), PMID: 7758108

- Gampe RT**, Montana VG, Lambert MH, Wisely GB, Milburn MV, Xu HE. 2000. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. *Genes & Development* **14**:2229–2241. DOI: <https://doi.org/10.1101/gad.802300>, PMID: 10970886
- Giner XC**, Cotnoir-White D, Mader S, Lévesque D. 2015. Selective ligand activity at nur/retinoid X receptor complexes revealed by dimer-specific bioluminescence resonance energy transfer-based sensors. *The FASEB Journal* **29**:4256–4267. DOI: <https://doi.org/10.1096/fj.14-259804>, PMID: 26148973
- Gronemeyer H**, Gustafsson JA, Laudet V. 2004. Principles for modulation of the nuclear receptor superfamily. *Nature Reviews. Drug Discovery* **3**:950–964. DOI: <https://doi.org/10.1038/nrd1551>, PMID: 15520817
- Hughes TS**, Giri PK, de Vera IMS, Marciano DP, Kuruvilla DS, Shin Y, Blayo A-L, Kamenecka TM, Burris TP, Griffin PR, Kojetin DJ. 2014. An alternate binding site for PPAR γ ligands. *Nature Communications* **5**:3571. DOI: <https://doi.org/10.1038/ncomms4571>, PMID: 24705063
- Iwawaki T**, Kohno K, Kobayashi K. 2000. Identification of a potential Nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. *Biochemical and Biophysical Research Communications* **274**:590–595. DOI: <https://doi.org/10.1006/bbrc.2000.3204>, PMID: 10924322
- Jeon SG**, Yoo A, Chun DW, Hong SB, Chung H, Kim JI, Moon M. 2020. The critical role of Nurr1 as a mediator and therapeutic target in Alzheimer's disease-related pathogenesis. *Aging and Disease* **11**:705–724. DOI: <https://doi.org/10.14336/AD.2019.0718>, PMID: 32489714
- Jiang C**, Wan X, He Y, Pan T, Jankovic J, Le W. 2005. Age-Dependent dopaminergic dysfunction in Nurr1 knockout mice. *Experimental Neurology* **191**:154–162. DOI: <https://doi.org/10.1016/j.expneurol.2004.08.035>, PMID: 15589522
- Keller S**, Vargas C, Zhao H, Piszczek G, Brautigam CA, Schuck P. 2012. High-Precision isothermal titration calorimetry with automated peak-shape analysis. *Analytical Chemistry* **84**:5066–5073. DOI: <https://doi.org/10.1021/ac3007522>, PMID: 22530732
- Kersten S**, Kelleher D, Chambon P, Gronemeyer H, Noy N. 1995a. Retinoid X receptor α forms tetramers in solution. *PNAS* **92**:8645–8649. DOI: <https://doi.org/10.1073/pnas.92.19.8645>, PMID: 7567990
- Kersten S**, Pan L, Chambon P, Gronemeyer H, Noy N. 1995b. Role of ligand in retinoid signaling. 9-cis-retinoic acid modulates the oligomeric state of the retinoid X receptor. *Biochemistry* **34**:13717–13721. DOI: <https://doi.org/10.1021/bi00042a001>, PMID: 7577963
- Kilu W**, Merk D, Steinhilber D, Proschak E, Heering J. 2021. Heterodimer formation with retinoic acid receptor RXR α modulates coactivator recruitment by peroxisome proliferator-activated receptor PPAR γ . *The Journal of Biological Chemistry* **297**:100814. DOI: <https://doi.org/10.1016/j.jbc.2021.100814>, PMID: 34081964
- Kim KS**, Kim CH, Hwang DY, Seo H, Chung S, Hong SJ, Lim JK, Anderson T, Isacson O. 2003. Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. *Journal of Neurochemistry* **85**:622–634. DOI: <https://doi.org/10.1046/j.1471-4159.2003.01671.x>, PMID: 12694388
- Kim C-H**, Han B-S, Moon J, Kim D-J, Shin J, Rajan S, Nguyen QT, Sohn M, Kim W-G, Han M, Jeong I, Kim K-S, Lee E-H, Tu Y, Naffin-Olivos JL, Park C-H, Ringe D, Yoon HS, Petsko GA, Kim K-S. 2015. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. *PNAS* **112**:8756–8761. DOI: <https://doi.org/10.1073/pnas.1509742112>, PMID: 26124091
- Kojetin DJ**, Burris TP. 2013. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. *Molecular Pharmacology* **83**:1–8. DOI: <https://doi.org/10.1124/mol.112.079285>, PMID: 22869589
- Kojetin DJ**, Matta-Camacho E, Hughes TS, Srinivasan S, Nwachukwu JC, Cavett V, Nowak J, Chalmers MJ, Marciano DP, Kamenecka TM, Shulman AI, Rance M, Griffin PR, Bruning JB, Nettles KW. 2015. Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. *Nature Communications* **6**:8013. DOI: <https://doi.org/10.1038/ncomms9013>, PMID: 26289479
- Kovrigin EL**. 2012. Nmr line shapes and multi-state binding equilibria. *Journal of Biomolecular NMR* **53**:257–270. DOI: <https://doi.org/10.1007/s10858-012-9636-3>, PMID: 22610542
- Lala DS**, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, Evans RM, Heyman RA. 1996. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. *Nature* **383**:450–453. DOI: <https://doi.org/10.1038/383450a0>, PMID: 8837780
- Lammi J**, Perlmann T, Aarnisalo P. 2008. Corepressor interaction differentiates the permissive and non-permissive retinoid X receptor heterodimers. *Archives of Biochemistry and Biophysics* **472**:105–114. DOI: <https://doi.org/10.1016/j.abb.2008.02.003>, PMID: 18282463
- Maciejewski MW**, Schuyler AD, Gryk MR, Moraru II, Romero PR, Ulrich EL, Eghbalnia HR, Livny M, Delaglio F, Hoch JC. 2017. NMRbox: a resource for biomolecular NMR computation. *Biophysical Journal* **112**:1529–1534. DOI: <https://doi.org/10.1016/j.bpj.2017.03.011>, PMID: 28445744
- McFarland K**, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES. 2013. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. *ACS Chemical Neuroscience* **4**:1430–1438. DOI: <https://doi.org/10.1021/cn400100f>, PMID: 24117438
- McPhail D**, Cooper A. 1997. Thermodynamics and kinetics of dissociation of ligand-induced dimers of vancomycin antibiotics. *Journal of the Chemical Society, Faraday Transactions* **93**:2283–2289. DOI: <https://doi.org/10.1039/a701327b>
- Michiels P**, Atkins K, Ludwig C, Whittaker S, van Dongen M, Günther U. 2010. Assignment of the orphan nuclear receptor Nurr1 by NMR. *Biomolecular NMR Assignments* **4**:101–105. DOI: <https://doi.org/10.1007/s12104-010-9210-4>, PMID: 20300892

- Moon M**, Jung ES, Jeon SG, Cha MY, Jang Y, Kim W, Lopes C, Mook-Jung I, Kim KS. 2019. Nurr1 (NR4A2) regulates Alzheimer's disease-related pathogenesis and cognitive function in the 5XFAD mouse model. *Aging Cell* **18**:e12866. DOI: <https://doi.org/10.1111/acer.12866>, PMID: 30515963
- Morita K**, Kawana K, Sodeyama M, Shimomura I, Kagechika H, Makishima M. 2005. Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1. *Biochemical Pharmacology* **71**:98–107. DOI: <https://doi.org/10.1016/j.bcp.2005.10.017>, PMID: 16288995
- Moutinho M**, Codocedo JF, Puntambekar SS, Landreth GE. 2019. Nuclear receptors as therapeutic targets for neurodegenerative diseases: lost in translation. *Annual Review of Pharmacology and Toxicology* **59**:237–261. DOI: <https://doi.org/10.1146/annurev-pharmtox-010818-021807>, PMID: 30208281
- Munoz-Tello P**, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ. 2020. Assessment of NR4A ligands that directly bind and modulate the orphan nuclear receptor Nurr1. *Journal of Medicinal Chemistry* **63**:15639–15654. DOI: <https://doi.org/10.1021/acs.jmedchem.0c00894>, PMID: 33289551
- Norris M**, Fetler B, Marchant J, Johnson BA. 2016. NMRfX processor: a cross-platform NMR data processing program. *Journal of Biomolecular NMR* **65**:205–216. DOI: <https://doi.org/10.1007/s10858-016-0049-6>, PMID: 27457481
- Perlmann T**, Jansson L. 1995. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and Nurr1. *Genes & Development* **9**:769–782. DOI: <https://doi.org/10.1101/gad.9.7.769>, PMID: 7705655
- Powell E**, Xu W. 2008. Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. *PNAS* **105**:19012–19017. DOI: <https://doi.org/10.1073/pnas.0807274105>, PMID: 19022902
- Rajan S**, Jang Y, Kim CH, Kim W, Toh HT, Jeon J, Song B, Serra A, Lescar J, Yoo JY, Beldar S, Ye H, Kang C, Liu XW, Feitosa M, Kim Y, Hwang D, Goh G, Lim KL, Park HM, et al. 2020. Pge1 and PGA1 bind to Nurr1 and activate its transcriptional function. *Nature Chemical Biology* **16**:876–886. DOI: <https://doi.org/10.1038/s41589-020-0553-6>, PMID: 32451509
- Rehó B**, Lau L, Mocsár G, Müller G, Fadel L, Brázda P, Nagy L, Tóth K, Vámosi G. 2020. Simultaneous mapping of molecular proximity and comobility reveals agonist-enhanced dimerization and DNA binding of nuclear receptors. *Analytical Chemistry* **92**:2207–2215. DOI: <https://doi.org/10.1021/acs.analchem.9b04902>, PMID: 31870146
- Sacchetti P**, Dwornik H, Formstecher P, Rachez C, Lefebvre P. 2002. Requirements for heterodimerization between the orphan nuclear receptor Nurr1 and retinoid X receptors. *The Journal of Biological Chemistry* **277**:35088–35096. DOI: <https://doi.org/10.1074/jbc.M205816200>, PMID: 12122012
- Savkur RS**, Burris TP. 2004. The coactivator LXXLL nuclear receptor recognition motif. *The Journal of Peptide Research* **63**:207–212. DOI: <https://doi.org/10.1111/j.1399-3011.2004.00126.x>, PMID: 15049832
- Scheepstra M**, Andrei SA, de Vries RMJM, Meijer FA, Ma J-N, Burstein ES, Olsson R, Ottmann C, Milroy L-G, Brunsveld L. 2017. Ligand dependent switch from RXR homo- to RXR-NURR1 heterodimerization. *ACS Chemical Neuroscience* **8**:2065–2077. DOI: <https://doi.org/10.1021/acschemneuro.7b00216>, PMID: 28691794
- Shang J**, Brust R, Griffin PR, Kamenecka TM, Kojetin DJ. 2019. Quantitative structural assessment of graded receptor agonism. *PNAS* **116**:22179–22188. DOI: <https://doi.org/10.1073/pnas.1909016116>, PMID: 31611383
- Spathis AD**, Asvos X, Ziavra D, Karampelas T, Topouzis S, Cournia Z, Qing X, Alexakos P, Smits LM, Dalla C, Rideout HJ, Schwamborn JC, Tamvakopoulos C, Fokas D, Vassilatis DK. 2017. Nurr1: RXRα heterodimer activation as monotherapy for Parkinson's disease. *PNAS* **114**:3999–4004. DOI: <https://doi.org/10.1073/pnas.1616874114>, PMID: 28348207
- Subauste JS**, Katz RW, Koenig RJ. 1994. Dna binding specificity and function of retinoid X receptor alpha. *The Journal of Biological Chemistry* **269**:30232–30237. DOI: [https://doi.org/10.1016/S0021-9258\(18\)43802-1](https://doi.org/10.1016/S0021-9258(18)43802-1), PMID: 7982932
- Sundén H**, Schäfer A, Scheepstra M, Leysen S, Malo M, Ma JN, Burstein ES, Ottmann C, Brunsveld L, Olsson R. 2016. Chiral dihydrobenzofuran acids show potent retinoid X receptor-nuclear receptor related 1 protein dimer activation. *Journal of Medicinal Chemistry* **59**:1232–1238. DOI: <https://doi.org/10.1021/acs.jmedchem.5b01702>, PMID: 26820900
- Tamrazi A**, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA. 2002. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. *Molecular Endocrinology* **16**:2706–2719. DOI: <https://doi.org/10.1210/me.2002-0250>, PMID: 12456792
- Wallen-Mackenzie A**, Mata de Urquiza A, Petersson S, Rodriguez FJ, Friling S, Wagner J, Ordentlich P, Lenggqvist J, Heyman RA, Arenas E, Perlmann T. 2003. Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. *Genes & Development* **17**:3036–3047. DOI: <https://doi.org/10.1101/gad.276003>, PMID: 14681209
- Wang Z**, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, Xu H, Walker NPC, Perlmann T. 2003. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. *Nature* **423**:555–560. DOI: <https://doi.org/10.1038/nature01645>, PMID: 12774125
- Wang J**, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, Chandraratna RA, Sanders ME, Janesick A, Blumberg B, Ward L, Ho L, Pasinetti GM. 2016. Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease. *Oncotarget* **7**:7469–7479. DOI: <https://doi.org/10.18632/oncotarget.7191>, PMID: 26862735
- Weikum ER**, Liu X, Ortlund EA. 2018. The nuclear receptor superfamily: a structural perspective. *Protein Science* **27**:1876–1892. DOI: <https://doi.org/10.1002/pro.3496>, PMID: 30109749

- Willems S**, Merk D. 2022. Medicinal chemistry and chemical biology of Nurr1 modulators: an emerging strategy in neurodegeneration. *Journal of Medicinal Chemistry* **65**:9548–9563. DOI: <https://doi.org/10.1021/acs.jmedchem.2c00585>, PMID: 35797147
- Wilson TE**, Fahrner TJ, Johnston M, Milbrandt J. 1991. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. *Science* **252**:1296–1300. DOI: <https://doi.org/10.1126/science.1925541>, PMID: 1925541
- Xie J**, He H, Kong W, Li Z, Gao Z, Xie D, Sun L, Fan X, Jiang X, Zheng Q, Li G, Zhu J, Zhu G. 2022. Targeting androgen receptor phase separation to overcome antiandrogen resistance. *Nature Chemical Biology* **18**:1341–1350. DOI: <https://doi.org/10.1038/s41589-022-01151-y>, PMID: 36229685
- Zetterström RH**, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. 1997. Dopamine neuron agenesis in nurr1-deficient mice. *Science* **276**:248–250. DOI: <https://doi.org/10.1126/science.276.5310.248>, PMID: 9092472
- Zhang H**, Chen L, Chen J, Jiang H, Shen X. 2011a. Structural basis for retinoic X receptor repression on the tetramer. *The Journal of Biological Chemistry* **286**:24593–24598. DOI: <https://doi.org/10.1074/jbc.M111.245498>, PMID: 21613212
- Zhang H**, Zhou R, Li L, Chen J, Chen L, Li C, Ding H, Yu L, Hu L, Jiang H, Shen X. 2011b. Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. *Journal of Biological Chemistry* **286**:1868–1875. DOI: <https://doi.org/10.1074/jbc.M110.166215>, PMID: 21084305
- Zhang J**, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR. 2011c. Dna binding alters coactivator interaction surfaces of the intact VDR-RXR complex. *Nature Structural & Molecular Biology* **18**:556–563. DOI: <https://doi.org/10.1038/nsmb.2046>, PMID: 21478866

Appendix 1

Appendix 1—key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Strain, strain background (<i>Escherichia coli</i>)	BL21(DE3)	Sigma-Aldrich	CMC0014	Electrocompetent cells
Cell line (<i>Homo sapiens</i>)	Human embryonic kidney epithelial	ATCC	CRL-11268	
Cell line (<i>Homo sapiens</i>)	SK-N-BE(2) neuroblastoma	ATCC	CRL-2271	
Chemical compound, drug	BRF110	Sigma-Aldrich	CAS 2095489-35-1	
Chemical compound, drug	HX600	Axon Medchem	CAS 172705-89-4	
Chemical compound, drug	9- <i>cis</i> -Retinoic acid	Cayman Chemicals	CAS 5300-03-8	
Chemical compound, drug	Bexarotene	Cayman Chemicals	CAS 153559-49-0	
Chemical compound, drug	LG100268	Cayman Chemicals	CAS 153559-76-3	
Chemical compound, drug	CD3254	Cayman Chemicals	CAS 196961-43-0	
Chemical compound, drug	SR11237	Tocris Bioscience	CAS 146670-40-8	
Chemical compound, drug	UVI3003	Cayman Chemicals	CAS 847239-17-2	
Chemical compound, drug	LG100754	Cayman Chemicals	CAS 180713-37-5	
Chemical compound, drug	IRX4204	MedChemExpress	CAS 220619-73-8	
Chemical compound, drug	Rhein	Sigma-Aldrich	CAS 478-43- 3	
Chemical compound, drug	HX531	Cayman Chemicals	CAS 188844-34-0	
Chemical compound, drug	Danthron	Sigma-Aldrich	CAS 117-10-2	
Chemical compound, drug	PA452	Tocris Bioscience	CAS 457657-34-0	
Peptide, recombinant protein	FITC-PGC1α	LifeTein		Amino acid sequence: EAEEPSLLKKLLAPANTQ, with an N-terminal FITC label and an amidated C-terminus.
Recombinant DNA reagent	Nurr1-ligand binding domain (LBD) (plasmid)	de Vera et al., 2016	Bacteria expression plasmid	
Recombinant DNA reagent	RXRα-ligand binding domain (LBD) (plasmid)	Kojetin et al., 2015	Bacteria expression plasmid	

Appendix 1 Continued on next page

Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Recombinant DNA reagent	pET45b(+)	Novagen	71327-3	
Transfected construct (<i>Photinus pyralis</i>)	3xNBRE-luciferase plasmid	de Vera et al., 2016	Sanger sequenced	
Transfected construct (<i>Photinus pyralis</i>)	3xDR1-luciferase plasmid	Hughes et al., 2014	Mammalian expression plasmid, Sanger sequenced	The 3xPPRE-luciferase reporter plasmid in the referenced paper was used in our study.
Transfected construct (human)	Full-length human Nurr1	de Vera et al., 2016	Mammalian expression plasmid, Sanger sequenced	
Transfected construct (human)	Full-length human RXR α in pCMV-Sport6 vector	Zhang et al., 2011c	Mammalian expression plasmid, Sanger sequenced	We obtained this plasmid from Griffin lab at UF Scripps Institute (see referenced paper).
Recombinant DNA reagent	pcDNA3.1 empty vector	Thermo Fisher Scientific	V790-20	
Sequence-based reagent	RXR α - Δ LBD-F	This paper	PCR primer ordered from Sigma	CAGCAGCGCCTAAGAGGACA TG
Sequence-based reagent	RXR α - Δ LBD-R	This paper	PCR primer ordered from Sigma	CATGTCCTCTTAGGCGCTGCTG
Sequence-based reagent	Δ NTD-RXR α -F	This paper	PCR primer ordered from Sigma	CCACCCCTCGAGAAACATGG
Sequence-based reagent	Δ NTD-RXR α -R	This paper	PCR primer ordered from Sigma	CCATGTTTCTCGAGGGGTGG
Gene (human)	Nurr1 (NR4A2)	Uniprot		Full length: residues 1–598; LBD: residues 353–598
Gene (human)	RXR α (NR2B1)	Uniprot		Full length: residues 1–462; LBD: 223–462
Sequence-based reagent	Restriction enzymes, ligase for cloning	NEB		XhoI, HindIII, T4 ligase
Commercial assay or kit	Gibson assembly	NBE	E2611L	
Commercial assay or kit	Britelite plus Reporter Gene Assay System	Perkin Elmer	6066769	

Appendix 1 Continued on next page

Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Sequence-based reagent	RXRα-LBD	This paper	gBlock for Gibson assembly	CCAGCACAGTGGCGGCCGCA TGAAGCGGGAAGCCGTGCAG GAGGAGCGGCAGCGTGGCAA GGACCGGAACGAGAATGAGG TGGAGTCGACCAGCAGCGCC AACGAGGACATGCCGGTGGGA GAGGATCCTGGAGGCTGAGC TGGCCGTGGAGCCCCAAGACC GAGACCTACGTGGAGGCAAA CATGGGGCTGAACCCCAGCT CGCCGAACGACCCTGTCACC AACATTTGCCAAGCAGCCGA CAAACAGCTTTTCACCCTGG TGGAGTGGGCCAAGCGGATC CCACACTTCTCAGAGCTGCC CCTGGACGACCAGGTCTATCC TGCTGCGGGCAGGCTGGAAT GAGCTGCTCATCGCCTCCTT CTCCCACCGCTCCATCGCCG TGAAGGACGGGATCCTCCTG GCCACCGGGCTGCACGTCCA CCGGAACAGCGCCCACAGCG CAGGGGTGGGCGCCATCTTT GACAGGGTGCTGACGGAGCT TGTGTCCAAGATGCGGGACA TGCAGATGGACAAGACGGAG CTGGGCTGCCTGCGCGCCAT CGTCCTCTTTAACCCCTGACT CCAAGGGGCTCTCGAACCCG GCCGAGGTGGAGGCGCTGAG GGAGAAGGTCTATGCGTCCT TGGAGGCCTACTGCAAGCAC AAGTACCCAGAGCAGCCGGG AAGGTTGCTAAGCTCTTGC TCCGCCTGCCGGCTCTGCGC TCCATCGGGCTCAATGCCT GGAACATCTCTTCTTCTCA AGCTCATCGGGGACACACCC ATTGACACCTTCCTTATGGA GATGCTGGAGGCGCCGCACC AAATGACTTGATCGAGTCTA GAGGGCCCCG
Commercial assay or kit	LanthaScreen Elite Tb-anti-His antibody	Thermo Fisher	#PV5895	
Software, algorithm	NITPIC software	Keller et al., 2012		Baseline calculation, curve integration
Software, algorithm	SEDPHAT	Brautigam et al., 2016		Estimation of binding affinity and thermodynamic parameter measurements
Software, algorithm	GUSSI	Brautigam, 2015		Plot ITC figures
Other	NMR chemical shift assignment of Nurr1 LBD	Michiels et al., 2010; de Vera et al., 2019; Munoz-Tello et al., 2020	BMRB16541	Published NMR peak assignment from Biological Magnetic Resonance Data Bank
Software, algorithm	NMRfX	Norris et al., 2016		NMR data process and analysis
Software, algorithm	NMR LineShapeKin version 4	Kovrigin, 2012		NMR lineshape analysis

Appendix 1 Continued on next page

Appendix 1 Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Software, algorithm	MATLAB R2022a via NMRbox	<i>Maciejewski et al., 2017</i>		NMR lineshape analysis
Software, algorithm	Pearson and Spearman correlation analysis	GraphPad Prism		Correlation analysis
Software, algorithm	Principal component analysis (PCA);	GraphPad Prism		Correlation analysis
Software, algorithm	ANOVA multiple comparison test	GraphPad Prism		Statistical testing